Search

everythinglearnresearchcommunity

for

Search:↓

Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.

The conversation discusses experiences with PRP and mesotherapy for hair loss. One user mentions both treatments were costly without significant results.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

Hair loss discussion includes treatments like Minoxidil, finasteride, and RU58841. Platelet rich plasma treatment is considered expensive but cheaper than hair transplant.

Finasteride users discuss potential side effects, including Post Finasteride Syndrome (PFS), with varying opinions on its legitimacy and impact. Some users report side effects like changes in semen consistency and reduced pre-ejaculate, while others emphasize the rarity and reversibility of side effects.

The conversation discusses patient updates on hair loss treatment with Verteporfin after five months, as reported by Dr. Blake Bloxham. Patients voluntarily sent their progress pictures to Dr. Bloxham.

The user has been taking finasteride for nearly two months and has noticed an increased urge to urinate with slight discomfort. They are questioning if this side effect is temporary.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

Breezula results are awaited, but no updates have been posted. Users are uncertain about its promise.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.

A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.

The conversation is about the delay in Breezula's phase 3 trials and skepticism regarding its effectiveness compared to other treatments like RU58841 and Pyrilutamide. Some users prefer safety over effectiveness, while others express frustration with the slow progress and doubt Breezula will be a significant treatment for hair loss.

The conversation is about the potential risk of permanent hair loss from PRP (platelet rich plasma) treatments and whether PRF (platelet rich fibrin) carries the same risk. The user is seeking information on this topic.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

A user experienced chest discomfort after taking finasteride for hair loss and is concerned about whether it is a side effect or an allergy. They are advised to consult a doctor and consider other hair loss treatments if necessary.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The user is seeking an alternative solvent for pyrilutamide due to skin irritation from ethanol and propylene glycol. They experienced similar issues with topical minoxidil.

After a second session of Platelet-Rich Plasma (PRP) treatment for hair regrowth, the user is experiencing increased shedding of thick and dark hairs and is concerned about whether this is temporary. They are seeking others' experiences with PRP, specifically regarding the duration of shedding and eventual positive outcomes.

Dr. Bloxham's 9-month update on FUT scar revision with Verteporfin shows promising results. Excitement is high for FUE, which appears highly effective based on Dr. Barghouthi's findings.

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

A user has been taking finasteride for 7 months and is experiencing watery semen as the only side effect. They are considering taking zinc supplements to improve this condition.